Allena Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Allena Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Allena Pharmaceuticals: 11 sponsored US clinical trials, none currently recruiting.

Allena Pharmaceuticals sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage).

Top-decile sponsor footprint

Allena Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

TERMINATED Phase 2

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

NCT04987294
COMPLETED Phase 2

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

NCT04987242
COMPLETED Phase 1

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

NCT04829435
COMPLETED Phase 1

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

NCT04236219
TERMINATED Phase 3

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

NCT03847090
COMPLETED Phase 2

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

NCT03391804
COMPLETED Phase 3

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

NCT03456830
COMPLETED NA

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

NCT03095885
COMPLETED Phase 2

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

NCT02547805
COMPLETED Phase 2

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

NCT02503345
COMPLETED Phase 2

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

NCT02289755

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6
Phase 3 2

How the Allena Pharmaceuticals early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 9 completed (82%).

Phase mix: 2 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Therapeutic area indexing for this sponsor is limited in the public registry.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Allena Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Allena Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Allena PharmaceuticalsAderans Research InstituteAegerion PharmaceuticalsAOBiomeArmata Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Allena Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Allena Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Allena Pharmaceuticals page

11 registered trials is a research-attention snapshot, not an endorsement of Allena Pharmaceuticals or any single study.

  • None of Allena Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Allena Pharmaceuticals pipeline card: 11 registered trials from official public datasets.Report a data error.